HONG KONG, Aug. 31 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," 801.HK), China's leading integrated healthcare enterprise, is pleased to announce that the Group is considering to list its shares on the Taiwan Stock Exchange through the issuance of Taiwan Depositary Receipts ("TDRs"), and has appointed Polaris Securities Co., Ltd. as the financial advisor for the proposed listing. The Group will become the first integrated healthcare company listed on Taiwan's stock market should the company proceed with the proposed TDR issuance upon obtaining relevant regulatory approval.
Mr. Kam Yuen, Chairman and Chief Executive Officer of the Group said that China's ongoing medical reform and the newly launched preferential trade agreement under Economic Cooperation Framework Agreement ("ECFA") has created a perfect window to encourage stronger strategic collaborations between Taiwan and China, amongst which, the sharing of corporate and human resources, etc.
Mr. Kam said that Taiwan's well developed healthcare insurance system as well as its world-class healthcare corporations can help to strengthen the Group's existing medical devices and healthcare services businesses in China. Citing closer collaborations between Taiwan and China which opens up numerous investment opportunities, the Group would like to leverage this opportunity to strengthen and speed up its business development initiatives, including knowledge-sharing of Taiwan's experience in the development of its healthcare industries, with similar attributes to China's development in many ways.
Based on the track records of other TDR issuances, Mr. Kam is confident that the Group will be able to enhance the liquidity of its shares while broadening its shareholder base, and enable quality investors from Taiwan to invest in Group's shares while promote the Group's corporate image in Taiwan.
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx). Thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities Golden Meditech has, over the years, established itself as a first-mover in China's healthcare industry with dominant positions in medical devices and healthcare services markets. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
For enquiries, please contact: Golding Meditech Holdings Limited Investor Relations Department Add: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong Tel: +852-3605-8180 Fax: +852-3605-8181 Email: firstname.lastname@example.org
SOURCE Golden Meditech Holdings Limited